{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:25:33Z","timestamp":1785767133983,"version":"3.56.0"},"update-to":[{"DOI":"10.1002\/14651858.cd003376.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000}}],"reference-count":113,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003376.pub4","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T07:28:22Z","timestamp":1712647702000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women"],"prefix":"10.1002","volume":"2024","author":[{"given":"George A","family":"Wells","sequence":"additional","affiliation":[{"name":"School of Epidemiology and Public Health; University of Ottawa; Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Ching","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Methods Center; University of Ottawa Heart Institute; Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Peterson","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Unit; Ottawa Civic Hospital \/ Loeb Research Institute; Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Zheng","sequence":"additional","affiliation":[{"name":"University of Ottawa Heart Institute; Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon E","family":"Kelly","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Methods Centre; University of Ottawa Heart Institute; Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverley","family":"Shea","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Community Medicine; University of Ottawa; Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Tugwell","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medicine; University of Ottawa; Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,4,9]]},"reference":[{"issue":"5","key":"10.1002\/14651858.CD003376.pub4-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/BF03343728","article-title":"Prevention of early postmenopausal bone loss with cyclical etidronate","volume":"23","author":"Adami","year":"2000","journal-title":"Journal of Endocrinological Investigation"},{"issue":"10","key":"10.1002\/14651858.CD003376.pub4-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1139\/y02-126","article-title":"The effect of strength training combined with bisphosphonate (etidronate) therapy on bone mineral, lean tissue, and fat mass in postmenopausal women","volume":"80","author":"Chilibeck","year":"2002","journal-title":"Canadian Journal of Physiology and Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD003376.pub4-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF01623376","article-title":"The effect of low-dose cyclical etidronate and calcium on bone mass in early postmenopausal women","volume":"3","author":"Evans","year":"1993","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s001980200135","article-title":"A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial","volume":"13","author":"Fukunaga","year":"2002","journal-title":"Osteoporosis International"},{"issue":"1","key":"10.1002\/14651858.CD003376.pub4-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S8756-3282(00)00303-3","article-title":"Cyclical etidronate versus sodium fluoride in established postmenopausal osteoporosis: a randomized 3 year trial","volume":"27","author":"Gua\u00f1abens","year":"2000","journal-title":"Bone"},{"issue":"1","key":"10.1002\/14651858.CD003376.pub4-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s002239900291","article-title":"Comparison of calcitriol treatment with etidronate-calcitriol and calcitonin-calcitriol combinations in Turkish women with postmenopausal osteoporosis: a prospective study","volume":"61","author":"G\u00fcrlek","year":"1997","journal-title":"Calcified Tissue International"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/BF01623239","article-title":"A comparison of the effects of oestrogen\/progestogen, high-dose oral calcium, intermittent cyclic etidronate and an ADFR regime on calcium kinetics and bone mass in postmenopausal women with spinal osteoporosis","volume":"4","author":"Hasling","year":"1994","journal-title":"Osteoporosis International"},{"issue":"1","key":"10.1002\/14651858.CD003376.pub4-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1385\/JCD:3:1:027","article-title":"The effects of cyclical etidronate on early postmenopausal bone loss: an open, randomized controlled study","volume":"3","author":"Heath","year":"2000","journal-title":"Journal of Clinical Densitometry"},{"issue":"2","key":"10.1002\/14651858.CD003376.pub4-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0002-9343(97)00019-3","article-title":"The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled study","volume":"103","author":"Herd","year":"1997","journal-title":"American Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD003376.pub4-BIB0010|cit10","first-page":"299","article-title":"Quality of life in the treatment assessment of postmenopausal osteoporosis","volume":"30","author":"Hu","year":"2005","journal-title":"Journal of Central South University (Medical Sciences)"},{"issue":"8","key":"10.1002\/14651858.CD003376.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.amjmed.2004.05.019","article-title":"Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: The Yamaguchi Osteoporosis Prevention Study","volume":"117","author":"Ishida","year":"2004","journal-title":"American Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD003376.pub4-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s007760100002","article-title":"Effect of menatetrenone on bone mineral density and incidence of vertebral fractures in postmenopausal women with osteoporosis: a comparison with the effect of etidronate","volume":"6","author":"Iwamoto","year":"2001","journal-title":"Journal of Orthopaedic Science"},{"issue":"4","key":"10.1002\/14651858.CD003376.pub4-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s00776-003-0655-5","article-title":"Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis","volume":"8","author":"Iwamoto","year":"2003","journal-title":"Journal of Orthopaedic Science"},{"issue":"6","key":"10.1002\/14651858.CD003376.pub4-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"750","DOI":"10.3349\/ymj.2005.46.6.750","article-title":"Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis","volume":"46","author":"Iwamoto","year":"2005","journal-title":"Yonsei Medical Journal"},{"issue":"2","key":"10.1002\/14651858.CD003376.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ijgo.2005.06.026","article-title":"Cyclical alendronate treatment in postmenopausal women with osteoporosis","volume":"91","author":"K\u00f6\u015f\u00fc\u015f","year":"2005","journal-title":"International Journal of Gynecology & Obstetrics"},{"issue":"4","key":"10.1002\/14651858.CD003376.pub4-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/BF02242451","article-title":"The effect of a modified etidronate cyclical regimen on postmenopausal osteoporosis: a four-year study","volume":"16","author":"Lyritis","year":"1997","journal-title":"Clinical Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD003376.pub4-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/ard.57.6.346","article-title":"Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women","volume":"57","author":"Masud","year":"1998","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"9","key":"10.1002\/14651858.CD003376.pub4-BIB0018|cit18","first-page":"2784","article-title":"Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up)","volume":"82","author":"Meunier","year":"1997","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD003376.pub4-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/BF01623461","article-title":"The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: results of three years of treatment","volume":"7","author":"Montessori","year":"1997","journal-title":"Osteoporosis International"},{"issue":"4","key":"10.1002\/14651858.CD003376.pub4-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1210\/jcem-66-4-747","article-title":"Coherence therapy does not prevent axial bone loss in osteoporotic women: a preliminary comparative study","volume":"66","author":"Pacifici","year":"1988","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"3","key":"10.1002\/14651858.CD003376.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF01622291","article-title":"Effects of cyclical etidronate therapy on bone loss in early postmenopausal women who are not undergoing hormonal replacement therapy","volume":"7","author":"Pouilles","year":"1997","journal-title":"Osteoporosis International"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003376.pub4-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/0167-4943(96)86998-6","article-title":"The use of bisphosphonates in the treatment of osteoporosis","volume":"22","author":"Russo","year":"1996","journal-title":"Archives of Gerontology and Geriatrics"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s001980070035","article-title":"A comparison of continuous alendronate, cyclical alendronate and cyclical etidronate with calcitriol in the treatment of postmenopausal vertebral osteoporosis: a randomized controlled trial","volume":"11","author":"Sahota","year":"2000","journal-title":"Osteoporosis International"},{"issue":"2","key":"10.1002\/14651858.CD003376.pub4-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s007760100060","article-title":"Effect of intermittent cyclical treatment with etidronate disodium (HEBP) and calcium plus alphacalcidol in postmenopausal osteoporosis","volume":"6","author":"Shiota","year":"2001","journal-title":"Journal of Orthopaedic Science"},{"issue":"3","key":"10.1002\/14651858.CD003376.pub4-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/8756-3282(91)90038-K","article-title":"The effects of etidronate on trabecular bone remodeling in postmenopausal spinal osteoporosis: a randomized study comparing intermittent treatment and an ADFR regime","volume":"12","author":"Steiniche","year":"1991","journal-title":"Bone"},{"issue":"18","key":"10.1002\/14651858.CD003376.pub4-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJM199005033221803","article-title":"Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis","volume":"322","author":"Storm","year":"1990","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD003376.pub4-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/oxfordjournals.rheumatology.a031451","article-title":"Cyclical etidronate prevents spinal bone loss in early post-menopausal women","volume":"36","author":"Tobias","year":"1997","journal-title":"British Journal of Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD003376.pub4-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0002-9343(93)90350-X","article-title":"Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy","volume":"95","author":"Harris","year":"1993","journal-title":"American Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD003376.pub4-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0002-9343(97)00278-7","article-title":"Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment","volume":"103","author":"Miller","year":"1997","journal-title":"American Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD003376.pub4-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199007123230201","article-title":"Intermittent cyclical etidronate treatment of postmenopausal osteoporosis","volume":"323","author":"Watts","year":"1990","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD003376.pub4-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0002-9343(99)80102-8","article-title":"Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study","volume":"99","author":"Wimalawansa","year":"1995","journal-title":"American Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD003376.pub4-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0002-9343(98)00029-1","article-title":"A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis","volume":"104","author":"Wimalawansa","year":"1998","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"S203","DOI":"10.1016\/j.bone.2010.04.481","article-title":"Apparent bone mineral density at femoral neck in the monitoring the early effects of teriparatide","volume":"47","author":"Caffarelli","year":"2010","journal-title":"Bone"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0034|cit34","first-page":"261","article-title":"Double-blind multicenter comparative study with alfacalcidol of etidronate disodium (EHDP) in involutional osteoporosis","volume":"21","author":"Fujita","year":"1993","journal-title":"Rinsho Hyoka (Clinical Evaluation)"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s00774-009-0035-0","article-title":"Comparison of the analgesic effects of bisphosphonates: Etidronate, alendronate and risedronate by electroalgometry utilizing the fall of skin impedance","volume":"27","author":"Fujita","year":"2009","journal-title":"Journal of Bone and Mineral Metabolism"},{"issue":"5","key":"10.1002\/14651858.CD003376.pub4-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/cpt1976205593","article-title":"Etidronate disodium in postmenopausal osteoporosis","volume":"20","author":"Heaney","year":"1976","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD003376.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/00002060-200206000-00010","article-title":"Beneficial effect of etidronate on bone loss after cessation of exercise in postmenopausal osteoporotic women","volume":"81","author":"Iwamoto","year":"2002","journal-title":"American Journal of Physical Medicine & Rehabilitation"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2302\/kjm.52.113","article-title":"Early response to alendronate after treatment with etidronate in postmenopausal women with osteoporosis","volume":"52","author":"Iwamoto","year":"2003","journal-title":"Keio Journal of Medicine"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00774-004-0509-z","article-title":"A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial","volume":"22","author":"Kushida","year":"2004","journal-title":"Journal of Bone and Mineral Metabolism"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"513\u201320","DOI":"10.1016\/S0002-9343(99)00062-5","article-title":"A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget\u2019s disease of bone. Paget\u2019s Risedronate\/Etidronate Study Group","volume":"106","author":"Miller","year":"1999","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0003-9993(97)90032-0","article-title":"Cyclical etidronate: Its effect on bone density in patients with acute spinal cord injury","volume":"78","author":"Pearson","year":"1997","journal-title":"Archives of Physical Medicine and Rehabilitation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003376.pub4-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/BF02500546","article-title":"Treatment of post-menopausal osteoporosis and low serum magnesium with intermittent cyclical EHDP and magnesium","volume":"6","author":"Struijs","year":"1996","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00776-004-0854-8","article-title":"Efficacy of different dosing schedules of etidronate for stress shielding after cementless total hip arthroplasty","volume":"10","author":"Yamaguchi","year":"2005","journal-title":"Journal of Orthopaedic Science"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0044|cit44","first-page":"5182","article-title":"Effects of combined treatment of rocaltrol, etidronate and sisterly on bone pain and bone mineral density in osteoporosis patients with vertebral fracture","volume":"8","author":"Zhu","year":"2004","journal-title":"Chinese Journal of Clinical Rehabilitation"},{"issue":"8","key":"10.1002\/14651858.CD003376.pub4-BIB0045|cit45","first-page":"593","article-title":"Effect of therapeutical association between hormone replacement therapy and cyclic intermittent therapy with etidronate about bone mineral content in women with postmenopausal osteoporosis","volume":"39","author":"Clemente","year":"1996","journal-title":"Progresos de Obstetricia y Ginecolog\u00eda"},{"issue":"3","key":"10.1002\/14651858.CD003376.pub4-BIB0046|cit46","first-page":"143","article-title":"Comparison of different therapeutic regimens in the treatment of patients with post menopausal osteoporosis","volume":"12","author":"Dogan","year":"2001","journal-title":"Journal of Rheumatology and Medical Rehabilitation"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0047|cit47","unstructured":"A comparison of incidences of vertebral fracture in Japanese patients with osteoporosis treated with etidronate and alfacalcidol; a randomized, double-blind study rctportal.niph.go.jp\/s\/detail\/um?trial_id=JapicCTI-050093#"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003376.pub4-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/BF02500554","article-title":"Long-term treatment of postmenopausal osteoporosis with sodium etidronate or calcitonin [abstract]","volume":"6","author":"Lozano-Tonkin","year":"1996","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00044011-200222020-00005","article-title":"Combination of intermittent cyclical etidronate and hormone replacement therapy for postmenopausal non-responders to estrogen","volume":"22","author":"Nozaki","year":"2002","journal-title":"Clinical Drug Investigation"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0050|cit50","unstructured":"Avenell A An influential osteoporosis study is \u201clikely fraudulent\u201d- but not retracted retractionwatch.com\/2020\/07\/02\/an-influential-osteoporosis-study-is-likely-fraudulent-but-not-retracted\/"},{"issue":"5","key":"10.1002\/14651858.CD003376.pub4-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1210\/jc.2019-00192","article-title":"Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network met-analysis","volume":"104","author":"Barrionuevo","year":"2019","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"7","key":"10.1002\/14651858.CD003376.pub4-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s001980170072","article-title":"An assessment tool for predicting fracture risk in postmenopausal women","volume":"12","author":"Black","year":"2001","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1002\/sim.6301","article-title":"The Peto odds ratio viewed as a new effect measure","volume":"33","author":"Brockhaus","year":"2014","journal-title":"Statistics in Medicine"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD003376.pub4-BIB0054|cit54","first-page":"1","article-title":"2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada","volume":"167","author":"Brown","year":"2002","journal-title":"Canadian Medical Association Journal"},{"issue":"7","key":"10.1002\/14651858.CD003376.pub4-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s001980070075","article-title":"Risk of mortality following clinical fractures","volume":"11","author":"Cauley","year":"2000","journal-title":"Osteoporosis International"},{"issue":"7","key":"10.1002\/14651858.CD003376.pub4-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"364","DOI":"10.11622\/smedj.2019028","article-title":"Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis: a systematic review","volume":"60","author":"Chandran","year":"2019","journal-title":"Singapore Medical Journal"},{"issue":"10","key":"10.1002\/14651858.CD003376.pub4-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"711","DOI":"10.7326\/M14-0317","article-title":"Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review","volume":"161","author":"Crandall","year":"2014","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD003376.pub4-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s001980170147","article-title":"A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis","volume":"12","author":"Cranney","year":"2001","journal-title":"Osteoporosis International"},{"issue":"11","key":"10.1002\/14651858.CD003376.pub4-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1001\/archinte.1989.00390110045010","article-title":"Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women","volume":"149","author":"Cummings","year":"1989","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0060|cit60","unstructured":"Deeks JJ Higgins JPT Chapter 10: Analysing data and undertaking meta-analyses. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0061|cit61","unstructured":"DistillerSR. Version 2.35 DistillerSR Inc 2023"},{"issue":"3","key":"10.1002\/14651858.CD003376.pub4-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1037\/h0087425","article-title":"The p-value fallacy and how to avoid it","volume":"57","author":"Dixon","year":"2003","journal-title":"Canadian Journal of Experimental Psychology"},{"issue":"1","key":"10.1002\/14651858.CD003376.pub4-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s001980170152","article-title":"Lifetime and five-year age-specific risks of first and subsequent osteoporotic fractures in postmenopausal women","volume":"12","author":"Doherty","year":"2001","journal-title":"Osteoporosis International"},{"issue":"4","key":"10.1002\/14651858.CD003376.pub4-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2106\/JBJS.K.01181","article-title":"Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project","volume":"95","author":"Edwards","year":"2013","journal-title":"Journal of Bone and Joint Surgery"},{"issue":"4","key":"10.1002\/14651858.CD003376.pub4-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jval.2014.01.008","article-title":"Bazedoxifene versus oral bisphosphonates for the prevention of nonvertebral fractures in postmenopausal women with osteoporosis at higher risk of fracture: a network meta-analysis","volume":"17","author":"Ellis","year":"2014","journal-title":"Value in Health"},{"issue":"7","key":"10.1002\/14651858.CD003376.pub4-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1359\/JBMR.050314","article-title":"What proportion of incident radiographic vertebral deformities is clinically diagnosed and vice versa?","volume":"20","author":"Fink","year":"2005","journal-title":"Journal of Bone and Mineral Research"},{"issue":"1","key":"10.1002\/14651858.CD003376.pub4-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/07853899708998743","article-title":"Bisphosphonates: preclinical aspects and use in osteoporosis","volume":"29","author":"Fleisch","year":"1997","journal-title":"Annals of Medicine"},{"issue":"Suppl","key":"10.1002\/14651858.CD003376.pub4-BIB0068|cit68","first-page":"317\u201321","article-title":"The ADFR concept and monitoring it","volume":"2","author":"Frost","year":"1980","journal-title":"Metabolic Bone Disease and Related Research"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0069|cit69","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2015"},{"issue":"4","key":"10.1002\/14651858.CD003376.pub4-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1385\/JCD:4:4:373","article-title":"Instant vertebral assessment: a noninvasive dual X-ray absorptiometry technique to avoid misclassification and clinical mismanagement of osteoporosis","volume":"4","author":"Greenspan S","year":"2001","journal-title":"Journal of Clinical Densitometry"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2249.2005.02665.x","article-title":"The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral bloodgdT cells in response to aminobisphosphonates is inhibited by statins","volume":"139","author":"Hewitt","year":"2005","journal-title":"Clinical and Experimental Immunology"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0072|cit72","unstructured":"Higgins JP Altman DG Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0073|cit73","unstructured":"Higgins JP Lasserson T Chandler J Tovey D Thomas J Flemyng E Methodological Expectations of Cochrane Intervention Reviews (MECIR); February 2022 Available at: community.cochrane.org\/sites\/default\/files\/uploads\/MECIR%20Version%20February%202022.pdf"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0074|cit74","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023 Available from www.training.cochrane.org\/handbook"},{"issue":"11","key":"10.1002\/14651858.CD003376.pub4-BIB0075|cit75","first-page":"1426","article-title":"Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date","volume":"166","author":"Hodsman","year":"2002","journal-title":"CMAJ"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/1471-2474-12-209","article-title":"The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women","volume":"12","author":"Hopkins","year":"2011","journal-title":"BMC Musculoskeletal Disorders"},{"issue":"4","key":"10.1002\/14651858.CD003376.pub4-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11914-007-0012-2","article-title":"Etidronate: what is its place in treatment of primary osteoporosis and other demineralizing diseases today?","volume":"5","author":"Ioachimescu","year":"2007","journal-title":"Current Osteoporosis Reports"},{"issue":"4","key":"10.1002\/14651858.CD003376.pub4-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.semarthrit.2010.06.001","article-title":"The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis","volume":"40","author":"Jansen","year":"2011","journal-title":"Seminars in Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","article-title":"An estimate of the worldwide prevalence and disability associated with osteoporotic fractures","volume":"17","author":"Johnell","year":"2006","journal-title":"Osteoporosis International"},{"issue":"1-2","key":"10.1002\/14651858.CD003376.pub4-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s11657-013-0144-1","article-title":"SCOPE: a scorecard for osteoporosis in Europe","volume":"8","author":"Kanis","year":"2013","journal-title":"Archives of Osteoporosis"},{"issue":"1","key":"10.1002\/14651858.CD003376.pub4-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s12603-015-0652-3","article-title":"Epidemiology and postoperative outcomes of atypical femoral fractures in older adults: a systematic review","volume":"21","author":"Khow","year":"2017","journal-title":"Journal of Nutrition, Health and Aging"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0082|cit82","unstructured":"Koziol M A shadow was cast on a bone researcher\u2019s work. What are journals doing about his papers? retractionwatch.com\/author\/michael-koziol\/"},{"issue":"9","key":"10.1002\/14651858.CD003376.pub4-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1359\/jbmr.090319","article-title":"Repeat low-trauma fractures occur frequently among men and women who have osteopenic BMD","volume":"24","author":"Langsetmo","year":"2009","journal-title":"Journal of Bone and Mineral Research"},{"issue":"3","key":"10.1002\/14651858.CD003376.pub4-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00198-013-2575-3","article-title":"Risk of osteonecrosis in patients taking bisphosphonates for prevention of osteoporosis: a systematic review and meta-analysis","volume":"25","author":"Lee","year":"2014","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0085|cit85","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Marshall C Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"6","key":"10.1002\/14651858.CD003376.pub4-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1002\/jcb.26550","article-title":"A network meta-analysis on the short-term efficacy and adverse events of different anti-osteoporosis for the treatment of postmenopausal osteoporosis","volume":"119","author":"Liu","year":"2018","journal-title":"Journal of Cell Biochemistry"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","article-title":"Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia","volume":"65","author":"Mavrokokki","year":"2007","journal-title":"Journal of Oral Maxillofacial Surgery"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS Peer Review of Electronic Search Strategies: 2015 guideline statement","volume":"75","author":"McGowan","year":"2016","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD003376.pub4-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1001\/archinternmed.2012.1796","article-title":"Increasing occurrence of atypical femoral fractures associated with bisphosphonate use","volume":"172","author":"Meier","year":"2012","journal-title":"Archives of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD003376.pub4-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1007\/s00198-012-2225-1","article-title":"Long-term mortality following fractures at different skeletal sites: a population-based cohort study","volume":"24","author":"Melton","year":"2013","journal-title":"Osteoporosis International"},{"issue":"5","key":"10.1002\/14651858.CD003376.pub4-BIB0091|cit91","first-page":"658","article-title":"Ranking antireabsorptive agents to prevent vertebral fractures in postmenopausal osteoporosis by mixed treatment comparison meta-analysis","volume":"17","author":"Migliore","year":"2013","journal-title":"European Review for Medical and Pharmacological Sciences"},{"issue":"5","key":"10.1002\/14651858.CD003376.pub4-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/ije\/21.5.837","article-title":"Intention-to-treat analysis: implications for quantitative and qualitative research","volume":"21","author":"Newell","year":"1992","journal-title":"International Journal of Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD003376.pub4-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"285","author":"NIH Consensus Development Panel on Osteoporosis Prevention","year":"2001","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0094|cit94","unstructured":"National Osteoporosis Guideline Group NOGG 2017: Clinical guideline for the prevention and treatment of osteoporosis National Osteoporosis Guideline Group"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1503\/cmaj.100771","article-title":"Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary","volume":"182","author":"Papaioannou","year":"2010","journal-title":"Canadian Medical Association Journal"},{"issue":"9","key":"10.1002\/14651858.CD003376.pub4-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1007\/s00198-006-0135-9","article-title":"The population burden of fractures originates in women with osteopenia, not osteoporosis","volume":"17","author":"Pasco","year":"2006","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0097|cit97","unstructured":"WebPlotDigitizer Version: 4.2 Rohatgi A San Francisco, California"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/S0140-6736(05)65132-X","article-title":"A tale of two worlds in prescribing etidronate for osteoporosis","volume":"350","author":"Rosen","year":"1997","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","article-title":"GRADE guideline 26: informative statements communicate the findings of systematic reviews of interventions","volume":"119","author":"Santesso","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0100|cit100","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0101|cit101","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"11","key":"10.1002\/14651858.CD003376.pub4-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.amjcard.2014.03.008","article-title":"Risk of atrial fibrillation with use of oral and intravenous bisphosphonates","volume":"113","author":"Sharma","year":"2014","journal-title":"American Journal of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD003376.pub4-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s00198-013-2576-2","article-title":"Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis","volume":"25","author":"Tadrous","year":"2014","journal-title":"Osteoporosis International"},{"issue":"3","key":"10.1002\/14651858.CD003376.pub4-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"262","DOI":"10.4065\/77.3.262","article-title":"Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials","volume":"77","author":"Taggart","year":"2002","journal-title":"Mayo Clinic Proceedings"},{"issue":"9","key":"10.1002\/14651858.CD003376.pub4-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/jbmr.3118","article-title":"Population-Wide Impact of Non-Hip Non-Vertebral Fractures on Mortality","volume":"32","author":"Tran","year":"2017","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11657-014-0182-3","article-title":"Estimating prevalence of osteoporosis: examples from industrialized countries","volume":"9","author":"Wade","year":"2014","journal-title":"Archives of Osteoporosis"},{"issue":"5","key":"10.1002\/14651858.CD003376.pub4-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1210\/jc.2004-1568","article-title":"Hip fracture in women withoutosteoporosis","volume":"90","author":"Wainwright","year":"2005","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0108|cit108","unstructured":"World Health Organization Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group World Health Organization Technical Report Series 1994 843 1 129"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0109|cit109","unstructured":"World Health Organization WHO scientific group on the assessment of osteoporosis at primary health care level: summary meeting report; 2004 Available at www.who.int\/chp\/topics\/Osteoporosis.pdf"},{"issue":"3-4","key":"10.1002\/14651858.CD003376.pub4-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1159\/000453138","article-title":"Network meta-analysis of pharmacological agents for osteoporosis treatment and fracture prevention","volume":"40","author":"Yang","year":"2016","journal-title":"Cellular Physiology and Biochemistry"},{"issue":"11","key":"10.1002\/14651858.CD003376.pub4-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1007\/s00198-016-3654-z","article-title":"Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses","volume":"27","author":"Zhou","year":"2016","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD003376.pub4-BIB0112|cit112","unstructured":"Wells GA Cranney A Bouchere M Peterson J Shea B Robinson V Bisphosphonates for the primary and secondary prevention of osteoporotic fractures in postmenopausal women: a meta-analysis [Technology report no. 69] Ottawa: Canadian Agency for Drugs and Technologies in Health 2006"},{"issue":"7","key":"10.1002\/14651858.CD003376.pub4-BIB0113|cit113","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003376.pub3","article-title":"Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women (Review)","author":"Wells","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T15:19:48Z","timestamp":1767194388000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD003376.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Musculoskeletal Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,4,9]]},"references-count":113,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003376.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,9]]}}}